Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The best kind of depression is a tropical depression
September 7, 2011
By: Gil Roth
President, Pharma & Biopharma Outsourcing Association
Thanks to Hurricane Irene, I nearly had to write this editorial by lamplight. My home was spared of wind or water damage, but we lost electricity for three days, starting at noon on Sunday, the day after the storm hit New York and New Jersey. A nearby friend — it was a localized outage, affecting around 500 homes and our local shoping strip — graciously offered to put us up, but as dusk settled that first evening and my wife and I read our Kindles by their in-case reading lamps, we decided that it would be just fine to stay in the dark. Our friend still invited us to come by and have some dinner and recharge our devices (Kindles, iPhones and iPads).
By the end of the second unelectric day, I’d achieved satori. I told myself I didn’t need electricity at home (well, not much), as long as I could drive somewhere to recharge and get online (didn’t want to bump up against my iPad’s 3G monthly data-limit, after all). In its wake, Irene left a mild climate, and the evenings were wonderfully cool, so air conditioning wasn’t a necessity.
Outside of the thrumming of some neighbors’ portable generators, the nights were quiet and dark and the sky was full of stars. Except for occasionally blinding myself with my iPhone’s LED-flashlight app while walking the dogs, I was pretty happy to take a little TV and internet shabbat.
All I had to worry about was the ticking time bomb of Temperature Excursion.
I had confidence in the integrity of the full-sized freezer in the garage. We had no reason to open that one up after the blackout, and I’d presciently stored several bags of ice in there before the blackout hit. The deep-frozen meats in there could probably survive a few days.
It was the refrigerator/freezer in the kitchen that troubled me. With each passing, powerless hour on Monday, its brushed steel gaze taunted us. “Why not open me up and see how cool your food is?” it seemed to say. “Don’t you want to get a little something from the cheese-drawer? Surely you won’t be letting out that much cool air . . .”
Tuesday morning was trash day, but our electric company predicted no power until at least Wednesday. Would I junk the ’fridge’s contents? Not even check to see if that herb-crusted salami was still good? Surely my wife’s sriracha would kill any microbe that came in contact with it!
And still the ’fridge stood, implacable, unadorned by kids’ crayon drawings or other magnet-bound decorations, looming over us like the Monolith from 2001: A Space Odyssey. Except potentially filled with pathogens.
I thought, “Kevin O’Donnell would never let me live it down if I got sick off of spoiled food while finishing the same issue that contains his Seven Signs of an Unhealthy Cold Chain article, plus another cold chain piece and a logistics interview!” Then I thought, “I may not live it down if I die from eating spoiled food!”
–GYR P.S.: The power didn’t get restored for another 20 hours. No lie: fewer than five hours after it got electricity back, the local McDonald’s had a line of customers outside its drive-through. They were craving food that had gone 60+ hours without refrigeration.
What I’m Reading
Online
How Novartis Plans to Avoid the ‘Patent Cliff’ Eva von Schaper, Bloomberg BusinessWeek – http://buswk.co/oM9X3E
Our #2 Top Pharma company faces $10 billion in lost revenue in the next few years due to generics. This short article details several of Novartis’ strategies to ameliorate that situation.
The impact of mergers on pharmaceutical R&D John L. LaMattina, Nature Reviews Drug Discovery – http://bit.ly/nGu4Wg
Comment: A scathing take on how M&A paralyzes pharma R&D. We hear this sort of indictment all the time, but this time it’s written by the former R&D president of Pfizer. He offers some followup to the article at his blog: http://johnlamattina.wordpress.com/
Non-Pharma
The Most Human Human, by Brian Christian Comment: I wrote about this book in my June column, vis-a-vis an interview I heard with its author. Among other topics, it’s about the way our interactions with computers and screens change the way we relate to people. There’s a fantastic chapter about chess and the development of opening theory that illustrates how we become less human even as we excel at the things that are supposed to make us rise above the animals.
What are you reading?
Let me know — at gil@rodpub.com, www.goodreads.com/groth, www.linkedin.com/groups?gid=1775433 or www.facebook.com/contractpharma — and the first respondent wins a prize!
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !